UCLB spin-out company, Biovex has been sold for $1 billion

UCLB are delighted to announce that US biotechnology giant Amgen have brought Biovex, a cancer vaccine developer for $1 billion. Biovex was founded a decade ago by Robert Coffin, a former UCL researcher who is now its Chief Technology Officer.

For the full press release, click here.